Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Relative Abundance Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Association with Transplant Outcomes

Najla H El Jurdi, MD, Ali Filali, PhD, Iman Salem, MD, Mauricio Retuerto, MS, Nina Dambrosio, CNP, Hillard M Lazarus, MD, Richard Creger, PharmD, Paolo F Caimi, MD, Brenda Cooper, MD, Ben Tomlinson, MD, Leland Metheny, MD, Ehsan Malek, MD, Folashade Otegbeye, MBBChir, MPH, Rafick-Pierre Sekaly, PhD, Mahmoud Ghannoum, PhD, Marcos de Lima, MD

Blood (2018) 132 (Supplement 1): 5754.

https://doi.org/10.1182/blood-2018-99-120125

Published: 2018

Journal Articles

Factors Influencing Incidence of Supraventricular Arrhythmias during and after Autologous Stem Cell Transplant in Multiple Myeloma

Megan Sturdy, MD, Rebecca Ye, BA, Trevor L Jenkins, MD, James Driscoll, MD PhD, Paolo Caimi, MD, Leland Metheny, MD, Rachel Zebrowski, RN, Nicole Ferrari, Merle Kolk, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2018) 132 (Supplement 1): 4834.

https://doi.org/10.1182/blood-2018-99-113828

Published: 2018

Journal Articles

Diversity and Richness Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Correlation with Transplant Outcomes

Najla H El Jurdi, MD, Ali Filali, PhD, Iman Salem, MD, Mauricio Retuerto, MS, Nina Dambrosio, CNP, Hillard M Lazarus, MD, Paolo F Caimi, MD, Richard Creger, PharmD, Brenda Cooper, MD, Ben Tomlinson, MD, Leland Metheny, MD, Ehsan Malek, MD, Folashade Otegbeye, MBBChir, MPH, Rafick-Pierre Sekaly, PhD, Mahmoud Ghannoum, PhD, Marcos de Lima, MD

Blood (2018) 132 (Supplement 1): 4627.

https://doi.org/10.1182/blood-2018-99-120038

Published: 2018

Journal Articles

Reducing Gastrointestinal Toxicity Associated with Autologous Transplantation for Multiple Myeloma without Compromising Its Anti-Myeloma Effect

Ehsan Malek, MD, Richard Creger, PhD, Merle Kolk, Fahrettin Covut, MD, Richard E Champlin, MD, Brenda W. Cooper, MD, Paolo Caimi, MD, Hillard M Lazarus, MD, Vinita Gupta, MD, Anant Vatsayan, MD MBBS, Qaiser Bashir, MD MBBS, Marcos De Lima, MD, Muzaffar H. Qazilbash, MD

Blood (2017) 130 (Supplement 1): 680.

https://doi.org/10.1182/blood.V130.Suppl_1.680.680

Published: 2017

Journal Articles

Optimizing Autologous Stem Cell Transplant for High-Risk Patients with Plasma Cell Dyscrasias

Naveed Ali, MD, Brenda W. Cooper, MD, Merle Kolk, Richard Creger, PhD, Gina Hoffman, Hillard M Lazarus, MD, Ben K. Tomlinson, MD, Paolo Caimi, MD, Leland Metheny, MD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2017) 130 (Supplement 1): 5656.

https://doi.org/10.1182/blood.V130.Suppl_1.5656.5656

Published: 2017

Journal Articles

Amifostine Reduces High-Dose Melphalan Induced Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplant (HCT) for Plasma Cell Myeloma

Vinita Gupta, MD, Hulya Armutlugoynuk, MD, Anant Vatsayan, MD MBBS, Paolo F. Caimi, MD, Brenda Cooper, MD, Leland Metheny, MD, Ehsan Malek, MD, Erica L. Campagnaro, MD, Stan Gerson, MD, Marcos de Lima, MD, Hillard M. Lazarus, MD, Richard J Creger, PharmD

Blood (2015) 126 (23): 5491.

https://doi.org/10.1182/blood.V126.23.5491.5491

Published: 2015

Journal Articles

Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study

Blood (2015) 126 (23): 5108.

https://doi.org/10.1182/blood.V126.23.5108.5108

Published: 2015

Journal Articles

Geriatric Assessment Driven Treatment In 149 AML Elderly Patients

Debora Capelli, MD, Francesco Saraceni, MD, Martina Chiarucci, MD, Antonella Poloni, Giorgia Mancini, MD, Silvia Trappolini, MD, Massimo Offidani, MD, Serena Rupoli, MD, Mauro Montanari, MD, Anna Rita Scortechini, MD, Guido Gini, MD, Ilaria Scortechini, MD, Giancarlo Discepoli, MD, Pietro Leoni, Prof., Attilio Olivieri, Prof.

Blood (2013) 122 (21): 3943.

https://doi.org/10.1182/blood.V122.21.3943.3943

Published: 2013

Journal Articles

Randomized Comparison of Melphalan 200 Mg/m 2 v. 280 Mg/m 2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

William I. Bensinger, MD, Pamela S Becker, MD, PhD, Ted A. Gooley, PhD, Thomas Chauncey, MD, PhD, David G. Maloney, MD, PhD, Robert Vescio, MD, Ajay K. Gopal, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD, Michael Lill, M.D., Leona Holmberg, MD, PhD, Jainulabdeen J Ifthikharuddin, MD, Gordon L. Phillips, II, MD

Blood (2012) 120 (21): 2009.

https://doi.org/10.1182/blood.V120.21.2009.2009

Published: 2012

Journal Articles

Efficacy and Feasibility of High-Dose Cytarabine Plus Idarubicin and Amifostine As Induction Schedule: A Prospective Observational Study of 100 AML Elderly Fit Patients

Debora Capelli, MD, Martina Chiarucci, MD, Francesco Saraceni, MD, Antonella Poloni, MD, Mauro Montanari, MD, Massimo Offidani, Serena Rupoli, MD, Anna Rita Scortechini, MD, Guido Gini, MD, Ilaria Scortechini, MD, Pietro Leoni, Prof., Attilio Olivieri, Prof.

Blood (2012) 120 (21): 3621.

https://doi.org/10.1182/blood.V120.21.3621.3621

Published: 2012

Journal Articles

Gemtuzumab-Ozogamicin as Post-Consolidation Therapy In Elderly Patients with Acute Myeloid Leukemia: a Pilot Study

Capelli Debora, Giorgia Mancini, Martina Chiarucci, Francesco Saraceni, Antonella Poloni, MD, Silvia Trappolini, Benedetta Costantini, Mauro Montanari, Guido Gini, Ilaria Scortechini, Pietro Leoni, MD, Attilio Olivieri

Blood (2010) 116 (21): 4357.

https://doi.org/10.1182/blood.V116.21.4357.4357

Published: 2010

Journal Articles

Cucurbitacin D Upregulates Fetal Hemoglobin Expression in K562 Cells and Human Erythroid Progenitors.

Hongtao Xing, PhD, Siwei Zhang, M.Phil., H. Phillip Koeffler, M.D., Ming Chiu Fung, Ph.D.

Blood (2007) 110 (11): 3833.

https://doi.org/10.1182/blood.V110.11.3833.3833

Published: 2007

Journal Articles

2006 RADAR Report Card on Conversion Rates from Accelerated FDA Approval to Regular FDA Approval for Drugs Used To Treat Hematologic Malignancies: Policy Changes Continue To Be Needed.

Andrew J. Lurie, BGS, Mark V. Mai, Martin S. Tallman, MD, June McCoy, MD JD MPH, Charles L. Bennett, MD PhD MPP

Blood (2006) 108 (11): 3318.

https://doi.org/10.1182/blood.V108.11.3318.3318

Published: 2006

Journal Articles

Is Amifostine Effective on the Protection of Mitoxantrone-Induced Acute Cardiotoxicity? A Biochemical and Histopathological Experimental Study.

Gurhan Kadikoylu, MD, Ibrahim Meteoglu, MD, Hulya Aybek, MD, Mete Kalak, MD, Suleyman Demir, MD, Muharrem Balkaya, PhD, Cigdem Yenisey, PhD, Zahit Bolaman, Mutlu Arat, MD

Blood (2006) 108 (11): 4364.

https://doi.org/10.1182/blood.V108.11.4364.4364

Published: 2006

Journal Articles

Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT).

Gordon L. Phillips, MD, Camille N. Abboud, MD, Steven H. Bernstein, MD, Jonathan W. Friedberg, MD, Michael W. Becker, MD, Jainulabdeen J. Ifthikharuddin, MD, Faith Young, MD, Jane L. Liesveld, MD

Blood (2006) 108 (11): 3076.

https://doi.org/10.1182/blood.V108.11.3076.3076

Published: 2006

Journal Articles

Ex Vivo Culture and Amifostine Effects in Human Cord Blood.

Hun-Mo Ryoo, MD, Sung Hwa Bae, MD, Kyung Hee Lee, MD, Myung Soo Hyun, MD

Blood (2006) 108 (11): 4153.

https://doi.org/10.1182/blood.V108.11.4153.4153

Published: 2006

Journal Articles

Myelodysplastic Syndromes (MDS): An International Practice and Treatment Survey.

Alan F. List, MD, for the MDS Foundation Inc.

Blood (2005) 106 (11): 2534.

https://doi.org/10.1182/blood.V106.11.2534.2534

Published: 2005

Journal Articles

Allogeneic and Matched Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies Using a Modified Reduced Intensity Conditioning Regimen.

Marion Raflores, MD, James Rossetti, DO, John Lister, MD, Richard Shadduck, MD, John Lech, DO, Robert Kaplan, MD, Margaret Kennedy, MD, Gisa Schunn, MD

Blood (2005) 106 (11): 5324.

https://doi.org/10.1182/blood.V106.11.5324.5324

Published: 2005

Journal Articles

Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS.

D. Haase, C. Steidl, J. Schanz, R. Schabla, M. Pfeilstöcker, T. Nösslinger, B. Hildebrandt, A. Kuendgen, M. Lübbert, B. Kunzmann, A. Giagounidis, C. Aul, L. Trümper, O. Krieger, C. Fonatsch, P. Valent, R. Stauder, U. Germing

Blood (2005) 106 (11): 787.

https://doi.org/10.1182/blood.V106.11.787.787

Published: 2005

Journal Articles

Effects of Amifostine and Fengling Polysaccharide on Proliferation and Chemoprotection of Human Granulocyte-Macrophage Progenitor Cells.

Bao-An Chen, PhD, Cheng-Yin Huang, MD, Chui-Ping Li, MD, Chong Gao, MD, Jia-Hua Ding, MD, Yun-Yu Sun, MD, Fei Fei, Ning-Na Chen

Blood (2005) 106 (11): 4190.

https://doi.org/10.1182/blood.V106.11.4190.4190

Published: 2005

NARROW

Relative Abundance Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Association with Transplant Outcomes

Factors Influencing Incidence of Supraventricular Arrhythmias during and after Autologous Stem Cell Transplant in Multiple Myeloma

Diversity and Richness Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Correlation with Transplant Outcomes

Reducing Gastrointestinal Toxicity Associated with Autologous Transplantation for Multiple Myeloma without Compromising Its Anti-Myeloma Effect

Optimizing Autologous Stem Cell Transplant for High-Risk Patients with Plasma Cell Dyscrasias

Amifostine Reduces High-Dose Melphalan Induced Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplant (HCT) for Plasma Cell Myeloma

Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study

Geriatric Assessment Driven Treatment In 149 AML Elderly Patients

Randomized Comparison of Melphalan 200 Mg/m 2 v. 280 Mg/m 2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Efficacy and Feasibility of High-Dose Cytarabine Plus Idarubicin and Amifostine As Induction Schedule: A Prospective Observational Study of 100 AML Elderly Fit Patients

Gemtuzumab-Ozogamicin as Post-Consolidation Therapy In Elderly Patients with Acute Myeloid Leukemia: a Pilot Study

Cucurbitacin D Upregulates Fetal Hemoglobin Expression in K562 Cells and Human Erythroid Progenitors.

2006 RADAR Report Card on Conversion Rates from Accelerated FDA Approval to Regular FDA Approval for Drugs Used To Treat Hematologic Malignancies: Policy Changes Continue To Be Needed.

Is Amifostine Effective on the Protection of Mitoxantrone-Induced Acute Cardiotoxicity? A Biochemical and Histopathological Experimental Study.

Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT).

Ex Vivo Culture and Amifostine Effects in Human Cord Blood.

Myelodysplastic Syndromes (MDS): An International Practice and Treatment Survey.

Allogeneic and Matched Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies Using a Modified Reduced Intensity Conditioning Regimen.

Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS.

Effects of Amifostine and Fengling Polysaccharide on Proliferation and Chemoprotection of Human Granulocyte-Macrophage Progenitor Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only